Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes J Vandesompele, K De Preter, F Pattyn, B Poppe, N Van Roy, ... Genome biology 3, 1-12, 2002 | 22193 | 2002 |
Mutational dynamics between primary and relapse neuroblastomas A Schramm, J Köster, Y Assenov, K Althoff, M Peifer, E Mahlow, ... Nature genetics 47 (8), 872-877, 2015 | 387 | 2015 |
Benchmarking of cell type deconvolution pipelines for transcriptomics data F Avila Cobos, J Alquicira-Hernandez, JE Powell, P Mestdagh, ... Nature communications 11 (1), 5650, 2020 | 364 | 2020 |
Meta-analysis of Neuroblastomas Reveals a Skewed ALK Mutation Spectrum in Tumors with MYCN Amplification S De Brouwer, K De Preter, C Kumps, P Zabrocki, M Porcu, ... Clinical cancer research 16 (17), 4353-4362, 2010 | 351 | 2010 |
Evaluation of qPCR curve analysis methods for reliable biomarker discovery: bias, resolution, precision, and implications JM Ruijter, MW Pfaffl, S Zhao, AN Spiess, G Boggy, J Blom, RG Rutledge, ... Methods 59 (1), 32-46, 2013 | 302 | 2013 |
Computational deconvolution of transcriptomics data from mixed cell populations F Avila Cobos, J Vandesompele, P Mestdagh, K De Preter Bioinformatics 34 (11), 1969-1979, 2018 | 232 | 2018 |
Measurable impact of RNA quality on gene expression results from quantitative PCR J Vermeulen, K De Preter, S Lefever, J Nuytens, F De Vloed, S Derveaux, ... Nucleic acids research 39 (9), e63-e63, 2011 | 220 | 2011 |
Targeted expression of mutated ALK induces neuroblastoma in transgenic mice LC Heukamp, T Thor, A Schramm, K De Preter, C Kumps, B De Wilde, ... Science translational medicine 4 (141), 141ra91-141ra91, 2012 | 207 | 2012 |
Asthma inflammatory phenotypes show differential microRNA expression in sputum T Maes, FA Cobos, F Schleich, V Sorbello, M Henket, K De Preter, ... Journal of Allergy and Clinical Immunology 137 (5), 1433-1446, 2016 | 205 | 2016 |
Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma J Vandesompele, M Baudis, K De Preter, N Van Roy, P Ambros, N Bown, ... Journal of clinical oncology 23 (10), 2280-2299, 2005 | 203 | 2005 |
Quantification of MYCN, DDX1, and NAG gene copy number in neuroblastoma using a real-time quantitative PCR assay K De Preter, F Speleman, V Combaret, J Lunec, G Laureys, BHJ Eussen, ... Modern Pathology 15 (2), 159-166, 2002 | 203 | 2002 |
Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study J Vermeulen, K De Preter, A Naranjo, L Vercruysse, N Van Roy, ... The lancet oncology 10 (7), 663-671, 2009 | 199 | 2009 |
Human fetal neuroblast and neuroblastoma transcriptome analysis confirms neuroblast origin and highlights neuroblastoma candidate genes K De Preter, J Vandesompele, P Heimann, N Yigit, S Beckman, ... Genome biology 7, 1-17, 2006 | 196 | 2006 |
Targeting MYCN-driven transcription by BET-bromodomain inhibition A Henssen, K Althoff, A Odersky, A Beckers, R Koche, F Speleman, ... Clinical Cancer Research 22 (10), 2470-2481, 2016 | 192 | 2016 |
An integrative genomics screen uncovers ncRNA T-UCR functions in neuroblastoma tumours P Mestdagh, E Fredlund, F Pattyn, A Rihani, T Van Maerken, J Vermeulen, ... Oncogene 29 (24), 3583-3592, 2010 | 182 | 2010 |
A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies K Althoff, A Beckers, E Bell, M Nortmeyer, T Thor, A Sprüssel, S Lindner, ... Oncogene 34 (26), 3357-3368, 2015 | 154 | 2015 |
MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors P Mestdagh, E Fredlund, F Pattyn, JH Schulte, D Muth, J Vermeulen, ... Oncogene 29 (9), 1394-1404, 2010 | 150 | 2010 |
Cross-cohort analysis identifies a TEAD4–MYCN positive feedback loop as the core regulatory element of high-risk neuroblastoma P Rajbhandari, G Lopez, C Capdevila, B Salvatori, J Yu, ... Cancer discovery 8 (5), 582-599, 2018 | 148 | 2018 |
Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma DR Carter, J Murray, BB Cheung, L Gamble, J Koach, J Tsang, S Sutton, ... Science translational medicine 7 (312), 312ra176-312ra176, 2015 | 138 | 2015 |
High ALK Receptor Tyrosine Kinase Expression Supersedes ALK Mutation as a Determining Factor of an Unfavorable Phenotype in Primary Neuroblastoma JH Schulte, HS Bachmann, B Brockmeyer, K DePreter, A Oberthür, ... Clinical Cancer Research 17 (15), 5082-5092, 2011 | 136 | 2011 |